Prolonged infusion of dexmedetomidine for sedation following tracheal resection

Summary Dexmedetomidine is a centrally acting alpha‐2 adrenergic agonist that is currently approved by the US Food and Drug Administration for short‐term use (≤24 h) to provide sedation in adults in the ICU. This drug has been shown to be efficacious in adult medical and surgical patients in providi...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric anesthesia 2005-07, Vol.15 (7), p.616-620
Main Authors: HAMMER, GREGORY B., PHILIP, BRIDGET M., SCHROEDER, ALAN R., ROSEN, FREDERICK S., KOLTAI, PETER J.
Format: Article
Language:English
Subjects:
alpha‐2 adrenergic agonists
Anesthesia
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
anxiolysis
Biological and medical sciences
Child
Conscious Sedation
dexmedetomidine
Dexmedetomidine - administration & dosage
Humans
Hypnotics and Sedatives - administration & dosage
Infusions, Intravenous
Laryngoscopy
Male
Medical sciences
Respiration, Artificial
Trachea - surgery
tracheal resection
Tracheal Stenosis - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Dexmedetomidine is a centrally acting alpha‐2 adrenergic agonist that is currently approved by the US Food and Drug Administration for short‐term use (≤24 h) to provide sedation in adults in the ICU. This drug has been shown to be efficacious in adult medical and surgical patients in providing sedation, anxiolysis, and analgesia. Dexmedetomidine has been associated with rapid onset and offset, hemodynamic stability, and a natural, sleep‐like state in mechanically ventilated adults. To date, there are few publications of the use of this drug in children, and prolonged infusion has not been described. We report our use of dexmedetomidine in a child during a 4‐day period of mechanical ventilation following tracheal reconstruction for subglottic stenosis.
ISSN:1155-5645
1460-9592
DOI:10.1111/j.1460-9592.2005.01656.x